IGEM Therapeutics appoints Dr David Chiswell as a Non-Executive Chairman

Cambridge Antibody Technology co-founder and CEO, Dr Chiswell brings 30 years of biotechnology experience to IGEM’s Board

London, 9 April 2019 – IGEM Therapeutics (IGEM), an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, announces that Dr David Chiswell will be joining IGEM as a Non-Executive Chairman effective immediately. Dr Chiswell brings more than 30 years’ experience in the biotechnology industry to IGEM’s Board.

Dr Chiswell co-founded Cambridge Antibody Technology (CAT) in 1990 where he served as CEO for six years. During his tenure he oversaw the company’s float on both the London Stock Exchange and Nasdaq in April 1997 and June 2001, respectively. Most recently Dr Chiswell was Chairman, then CEO of Kymab Ltd from 2015 to 2018. He is a past chairman of the UK BioIndustry Association (BIA) and his contributions to the field were recognised in 2006 when he was awarded an OBE for services to the biotechnology industry.

IGEM’s current Chairman, Peter Finan of Epidarex Capital, will remain on the board as a Non-Executive Director after Dr Chiswell joins.

Commenting on the appointment, Dr Tim Wilson, Chief Executive Officer of IGEM, said:
“We are thrilled to have Dr Chiswell joining our Board of Directors. His in-depth knowledge of therapeutic antibody discovery and development as well as his extensive experience leading the growth of early-stage biotechnology companies will make him an invaluable member of our team. I look forward to working with him and the rest of our Board. Additionally, I would like to thank Peter for Chairing the company with distinction over the past two years.”

Dr Chiswell, added:
“I am delighted to be joining IGEM Therapeutics as Non-Executive Chairman. IGEM’s management team has a strong vision for the future and I look forward to working with them to evolve it further as they develop their exciting pipeline of immunoglobulin E antibodies to address a number of significantly unmet areas in oncology.”

About IGEM Therapeutics

IGEM is a UK immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer. Unlike immunoglobulin G (IgG), IgE has evolved to kill tissue-dwelling multicellular parasites endowing it with several key features that make it ideal for the treatment of solid tumours.

IGEM is a spin out of King’s College London and has an ongoing collaboration with Dr Sophia Karagiannis, a global leader in the understanding of IgE antibodies. The company has raised Series A finance from Epidarex Capital, ALSA Holdings and the UCL Technology Fund.

For more information please contact:

Tim Wilson
Chief Executive Officer
IGEM Therapeutics
tim@igemtherapeutics.com
+44 (0)20 3078 9675

Communications advisor to IGEM Therapeutics:
Simon Conway
FTI Consulting
IGEMTherapeutics@fticonsulting.com
+44 (0)20 3727 1000